First Report of Response to Tarlatamab in a Patient With DLL3-Positive Pulmonary Carcinoid: Case Report

First Report of Response to Tarlatamab in a Patient With DLL3-Positive Pulmonary Carcinoid: Case Report

Tarlatamab, a DLL3-targeting bispecific T-cell engager, has rapidly assumed the role of a new standard of care in the later-line treatment of extensive-stage SCLC. Little is known about the efficacy of tarlatamab in other histologies such as DLL3-expressing metastatic pulmonary carcinoid tumor, a cl...

Full description

Saved in:
Bibliographic Details
Main Authors: Alissa J. Cooper, MD, Natasha Rekhtman, MD, PhD, Marina K. Baine, MD, PhD, Marie C. Thomas, DNP, FNP-C, Alia C. Lynch, PharmD, BCOP, Ryan D. Gentzler, MD, MS
Format: Article
Language:English
Published: Elsevier 2024-12-01
Series:JTO Clinical and Research Reports
Subjects:
Carcinoid
Neuroendocrine
Tarlatamab
Case report
Online Access:http://www.sciencedirect.com/science/article/pii/S2666364324001206
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items